<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.87104</article-id><article-id pub-id-type="publisher-id">ACM-26792</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180700000_90695170.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  miRNAs在精神分裂症临床诊断及预后中的研究进展
  The Diagnosis and Prognosis Research Pro-gress of miRNAs in Schizophrenia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>石</surname><given-names>丛丛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>丽敏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>山东省精神卫生中心三病房，山东 济南</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>09</month><year>2018</year></pub-date><volume>08</volume><issue>07</issue><fpage>622</fpage><lpage>626</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    精神分裂症是目前世界上让患者家庭承受最重的经济负担疾病之一，缺乏有效的分子标志物对其进行早期诊断及预后监测。微小RNA (miRNA)是一类约19至25个碱基长度的内源性非编码单链小分子RNA，转录后水平影响基因表达。有研究指出，miRNA在精神分裂症的发生、发展中起到重要作用，从而说明miRNA有可能作成为诊断和监测精神分裂症的预后新型分子标志物及新靶点。本文主要从以下三个方面简述miRNA与精神分裂症密切关系，并展望将来在临床的应用。
    Schizophrenia is one of the most economically burdened diseases in the world for patients and families. There are no effective molecular markers for early diagnosis and prognosis monitoring. Micro RNAs (miRNAs) are a class of endogenous non-coding single-stranded small RNAs of about 19 to 25 bases in length whose expression is affected by post-transcriptional levels. Previous studies have shown that miRNAs are closely related to the occurrence and development of schizophrenia, suggesting that miRNAs can be used as novel molecular markers for early diagnosis and prognosis monitoring of schizophrenia as well as new targets for molecular therapy. This paper systematically elucidates the mechanisms related to miRNA and schizophrenia from these three aspects, and looks forward to its clinical application. 
  
 
</p></abstract><kwd-group><kwd>微小RNA，精神分裂症，早期诊断，预后, MiRNA</kwd><kwd> Schizophrenia</kwd><kwd> Early Diagnosis</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>miRNAs在精神分裂症临床诊断及预后中的研究进展<sup> </sup></title><p>石丛丛，李静，杨丽敏<sup>*</sup></p><p>山东省精神卫生中心三病房，山东 济南</p><p><img src="//html.hanspub.org/file/4-1570673x1_hanspub.png" /></p><p>收稿日期：2018年8月16日；录用日期：2018年9月6日；发布日期：2018年9月13日</p><disp-formula id="hanspub.26792-formula24"><graphic xlink:href="//html.hanspub.org/file/4-1570673x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>精神分裂症是目前世界上让患者家庭承受最重的经济负担疾病之一，缺乏有效的分子标志物对其进行早期诊断及预后监测。微小RNA (miRNA)是一类约19至25个碱基长度的内源性非编码单链小分子RNA，转录后水平影响基因表达。有研究指出，miRNA在精神分裂症的发生、发展中起到重要作用，从而说明miRNA有可能作成为诊断和监测精神分裂症的预后新型分子标志物及新靶点。本文主要从以下三个方面简述miRNA与精神分裂症密切关系，并展望将来在临床的应用。</p><p>关键词 :微小RNA，精神分裂症，早期诊断，预后</p><disp-formula id="hanspub.26792-formula25"><graphic xlink:href="//html.hanspub.org/file/4-1570673x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1570673x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1570673x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>精神分裂症在众多的精神疾病中是比较严重和复杂一种疾病，发病率差不多1% [<xref ref-type="bibr" rid="hanspub.26792-ref1">1</xref>] ，表现为幻觉、神经生理功能及认知功能障碍和妄想等临床表现，患者经济负担沉重。精神分裂症以临床症状可分为两型，其中I型为阳性症状患者，有幻觉和妄想等症状，II型患者为阴性症状患者，有情感淡漠、主动性缺乏等体征。近些年来，随着多学科技术的发展，人类对精神分裂症的认识不能单纯局限于基因和细胞学层面，其病理生理机制研究越来越广泛 [<xref ref-type="bibr" rid="hanspub.26792-ref2">2</xref>] 。</p><p>Micro RNA (miRNA)是大多数在大脑中表达一类非编码小分子RNA，约70%左右；既往研究指出，miRNA参与大脑发育过程中突触形成、神经生长和记忆调节等信号通路，起到主导作用 [<xref ref-type="bibr" rid="hanspub.26792-ref3">3</xref>] 。随着miRNA的研究，大量临床研究表明，精神疾病的发生发展与miRNA关系密切，有望成为精神疾病的诊断有效的标记物及药物治疗靶点。越来越多的研究证实，与健康对照组患者相比，外周血miRNA在精神分裂症患者中存在过度表达情况，差异具有统计学意义 [<xref ref-type="bibr" rid="hanspub.26792-ref4">4</xref>] 。由于循环miRNA具有稳定性及表达特异性等优点，取材方便，其临床无创特点优势突出，逐渐受到人们的重视，应用广泛。本文将对循环miRNA在精神分裂症诊断及预后方面的研究进展进行综述。</p></sec><sec id="s4"><title>2. miRNA的作用</title><p>微小RNA (miRNA)是一类约19至25个碱基长度的内源性非编码单链小分子RNA，转录后水平影响基因表达。miRNA在人体内广泛存在，机体所有的生物调控过程几乎离不开它，包括参与细胞增殖、凋亡、神经发育、机体代谢等过程等 [<xref ref-type="bibr" rid="hanspub.26792-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.26792-ref6">6</xref>] 。研究报道 [<xref ref-type="bibr" rid="hanspub.26792-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.26792-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.26792-ref9">9</xref>] ，在精神分裂症患者的尸脑中，发现miRNA表达存在上调和下调的现象，从而说明异常表达的miRNA可以作为精神分裂症的诊断标志物。一些脑疾病的患者，在检查中发生外周血中存在特异性miRNA，并且与疾病的严重性成正相关 [<xref ref-type="bibr" rid="hanspub.26792-ref10">10</xref>] 。</p><p>最新研究表明，血浆miRNA也参与精神分裂症等多种疾病的侵袭与增殖过程，并发挥重要的作用 [<xref ref-type="bibr" rid="hanspub.26792-ref10">10</xref>] ，这些实验结果进一步为miRNA成为分子靶向治疗的血浆生物标记物奠定理论基础。</p></sec><sec id="s5"><title>3. 血浆miRNAs表达与精神分裂症</title><p>随着人体组织miRNAs被克隆和分子生物学的发展, 人类对疾病研究以深入到分子领域，一些常见如肿瘤、内分泌疾病、神经发育障碍等可能与miRNAs密切相关。Glinsky [<xref ref-type="bibr" rid="hanspub.26792-ref11">11</xref>] 等学者一项临床荟萃研究表明，通过对精神分裂症等常见的疾病绘制miRNAs图谱，指出精神分裂症受DNA结构变异的影响，而miRNAs调控在DNA结构变异中发挥重要作用。组织miRNA检测由于受损伤大，假阴性等特点，在临床中的应用较少。有研究表明，miRNA以非囊泡复合体的形式存在，具有结构稳定、取材方便等特点，因此备受关注，广泛应用 [<xref ref-type="bibr" rid="hanspub.26792-ref12">12</xref>] 。例如，许多文献报道精神分裂症患者外周血miRNA与健康对照组表达存在差异，说明miRNA在精神分裂中具有重要意义。通过分析800例人群miRNA分析分析表明，miR-130b和miR-193a-3p在精神分裂症患者组呈现高表达状态，而其他两组呈现低表达 [<xref ref-type="bibr" rid="hanspub.26792-ref13">13</xref>] 。Dinan [<xref ref-type="bibr" rid="hanspub.26792-ref14">14</xref>] 研究表明，不同微小RNA与不同的精神疾病呈现相关性，其中精神分裂症以miR-181、miR-346和miR-195为代表，miR-34a和miR-144则与双相障碍相关，而miR-219可能与二者都密切相关。</p><p>多项研究证明 [<xref ref-type="bibr" rid="hanspub.26792-ref15">15</xref>] ，精神分裂症与miRNA基因多态性存在相关，Ripke等通过分析包含精神分裂和正常人群的全基因组，精神分裂症关联呈现最强的关系是在1p21.3 (rs1,625,579)编码初级转录miRNA-137的基因 [<xref ref-type="bibr" rid="hanspub.26792-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.26792-ref17">17</xref>] ，而miRNA-137对在神经发育过程中起到调节作用。目前，不少研究报道一些miRNA-137的靶基因与精神分裂症关系密切，如TCF4、CACNA1C、钙通道等。研究报道指出，miRNA-137的多态性具有遗传特异性，能够影响精神分裂症家族史的患者的脑激活及脑功能连接情况，而没有家族史的人群则不受影响。miRNA-137既能调节神经元干细胞的增殖和分化 [<xref ref-type="bibr" rid="hanspub.26792-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.26792-ref19">19</xref>] ，又与精神分裂症的密切相关。另外，研究发现精神分裂症的发生和miRNA的多态性相关，如miRNA-206、miRNA-498和miRNA-198等。</p></sec><sec id="s6"><title>4. miRNA与精神分裂症的治疗</title><p>众多文献报道，miRNA在精神分裂症的产生及进展、预后中起到重要作用 [<xref ref-type="bibr" rid="hanspub.26792-ref20">20</xref>] 。进一步研究发现，在精神分裂症中，miRNA既能早期诊断和监测预后，又可以通过干预神经细胞生长发育过程来治疗疾病。</p><p>最近，多项研究表明，在服用抗精神病药物治疗前后部分miRNA的表达水平存此差异，部分精神分裂症患者在用药前后miRNA表达呈下降趋势，随着用药时间延长，下降的趋势越来越明显 [<xref ref-type="bibr" rid="hanspub.26792-ref21">21</xref>] 。Lai研究报道指出，患者在服用抗精神病药物后，并不是所有的miRNA表达水平会下降，在外周血及脑组织miRNA表达的差异，有7种miRNA表达水平没有改变，由此表明有些miRNA可作为精神分裂症疾病诊断的分子标记物 [<xref ref-type="bibr" rid="hanspub.26792-ref22">22</xref>] 。而最近有研究将焦点由治疗前后的表达差异转向治疗的耐药性方面，miR-301a-3p和miR-181b-5p在治疗耐药组与正常对照组相比表达增加，而在用药有应答组与正常组对比表达减少，而耐药组患者得GRIA2基因的表达水平呈现降低，进一步研究发现miR-181b-5p可能沉默与神经传递有关GRIA2基因的表达 [<xref ref-type="bibr" rid="hanspub.26792-ref23">23</xref>] 。以上分析说明，这些miRNA可以成为监测精神分裂症药物治疗反应性的潜在指标，而精神分裂症治疗的新方向可以通过调控miRNA的表达方面入手。</p></sec><sec id="s7"><title>5. miRNA与精神分裂症的预后</title><p>临床上主要根据患者情感控制能力、思维敏捷度、认知能力、意志力等评分综合判断预后，但是阴性症状具有许多不确定性，并不能对精神分裂症做出准确的预测。近年来，精神分裂症发病复杂，未能彻底透彻研究其药理作用机制，并且精神分裂症的药物涉及多个治疗系统，没有针对性，导致治疗上的缺陷。目前，随着分子水平的发展，miRNA的研究逐渐成为热点，涉及各种疾病，引导我们开发思路，指引我们从分子水平研究精神分裂症，为此有研究报道miRNA与精神分裂症关系密切，有可能精神药物存在潜在的治疗靶点 [<xref ref-type="bibr" rid="hanspub.26792-ref24">24</xref>] 。相关研究报道，抗精神病药物干预会使一些miRNA的表达水平发生改变，其中以Zhou等 [<xref ref-type="bibr" rid="hanspub.26792-ref25">25</xref>] 研究为代表性，该试验主要说明了miRNA表达水平受大鼠海马区在锂盐或丙戊酸钠影响。</p><p>有研究为了证明微小RNA能否为成为精神分裂症的分子标记物，运用PCR 技术定时定量分析不同服药时期精神分裂症患者血浆miRNA表达水平的变化，观察临床表现，并记录数值，提供临床依据。在患者口服抗精神病药过程中，miRNA监测值随着用药进行成下降趋势，最后恢复到人体正常值，从而说明随着用药的进行miRNA表达水平出现特征性变化的特点。有临床试验表明，部分精神分裂症患者的临床表现的症状逐渐减轻，病情呈现好转的趋势，在此过程中miRNA表达量逐渐降低恢复到正常水平。有研究表明，越来越多的微小RNA联合监测可以监测精神分裂症的临床疾病状态，预测疗效和预后，其中以miR-30e、miR-181b和miR-132表现最明显 [<xref ref-type="bibr" rid="hanspub.26792-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.26792-ref27">27</xref>] 。</p></sec><sec id="s8"><title>6. 小结</title><p>研究证明，与传统方法比较，在早期发现精神分裂症、评价治疗的疗效以及综合治疗中微小RNA的优势很明显，为治疗精神分裂症的研究提供新的思维方式。精神分裂症是一多因素疾病，大多数因为一些炎性细胞因子、神经传输递质、遗传基因、环境作用等多种因素共同作用下产生的，miRNA的理论及发病机制为精神分裂症提供了新的治疗研究方向。由于每类miRNA分子都可能作用于多个靶点，产生多种效应，因此探索关于精神分裂症治疗的特异性miRNA靶点以及具体作用机制是我们需要深入研究的问题。即便此研究过程具有重重困难，但应该看到调节miRNA的表达对精神分裂症的治疗具有巨大的探索价值和广阔的应用情景，通过不懈努力，一定可以攻破精神分裂症这个难关。</p></sec><sec id="s9"><title>文章引用</title><p>石丛丛,李 静,杨丽敏. miRNAs在精神分裂症临床诊断及预后中的研究进展 The Diagnosis and Prognosis Research Pro-gress of miRNAs in Schizophrenia[J]. 临床医学进展, 2018, 08(07): 622-626. https://doi.org/10.12677/ACM.2018.87104</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.26792-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Perkins, D.O., Jeffries, C.D., Jarskog, L.F., et al. (2013) Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of Risk Loci with Shared Effects on Five Major Psychiatric Disorders: A Genome-Wide Analysis. Lancet, 381, 1371-1379.</mixed-citation></ref><ref id="hanspub.26792-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Schreiber, R. and Newman-Tancredi, A. (2014) Improving Cognition in Schizophrenia with Antipsychotics that Elicit Neurogenesis through 5-HT(1A) Receptor Activation. Neurobiology of Learning and Memory, 110, 72-80.</mixed-citation></ref><ref id="hanspub.26792-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Sandoval, J., Díaz-Lagares, A., Salgado, R., et al. (2015) MicroRNA Expression Profiling and DNA Methylation Signature Forderegulated MicroRNA in Cutaneous T-Cell Lymphom. Journal of Investigative Dermatology, 135, 1128-1137.</mixed-citation></ref><ref id="hanspub.26792-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Pedroza-Torres, A., López-Urrutia, E., García-Castillo, V., et al. (2014) MicroRNAs in Cervical Cancer: Evidences for a miRNA Profile Deregulated by HPV and Its Impact on Radio-Resistance. Molecules, 19, 6263-6281.  
&lt;br&gt;https://doi.org/10.3390/molecules19056263</mixed-citation></ref><ref id="hanspub.26792-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Shi, Y., Zhao, X., Hsieh, J., et al. (2010) MicroRNA Regulation of Neural Stem Cells and Neurogenesis. Journal of Neuroscience, 30, 14931-14936.</mixed-citation></ref><ref id="hanspub.26792-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lang, M.F. and Shi, Y. (2012) Dynamic Roles of MicroRNAs in Neurogenesis. Frontiers in Neuroscience, 6, 71.</mixed-citation></ref><ref id="hanspub.26792-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Miller, B.H., Zeier, Z., Xi, L., et al. (2012) MicroRNA-132 Dysregulation in Schizophrenia Has Implications for Both Neurodevelopment and Adult Brain Function. Proceedings of the National Academy of Sciences of the United States of America, 109, 3125-3130.</mixed-citation></ref><ref id="hanspub.26792-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Santarelli, D.M., Beveridge, N.J., Tooney, P.A., et al. (2011) Upregulation of Dicer and MicroRNA Expression in the Dorsolateral Prefrontal Cortex Brodmann Area 46 in Schizophrenia. Biological Psychiatry, 69, 180-187.  
&lt;br&gt;https://doi.org/10.1016/j.biopsych.2010.09.030</mixed-citation></ref><ref id="hanspub.26792-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wong, J., Duncan, C.E., Beveridge, N.J., et al. (2013) Ex-pression of NPAS3 in the Human Cortex and Evidence of Its Posttranscriptional Regulation by miR-17 During Devel-opment, with Implications for Schizophrenia. Schizophrenia Bulletin, 39, 396-406. &lt;br&gt;https://doi.org/10.1093/schbul/sbr177</mixed-citation></ref><ref id="hanspub.26792-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lett, T.A., Chakavarty, M.M., Felsky, D., et al. (2013) The Ge-nome-Wide Supported MicroRNA-137 Variant Predicts Phenotypic Heterogeneity within Schizophrenia. Molecular Psychiatry, 18, 443-450.</mixed-citation></ref><ref id="hanspub.26792-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Fujiwara, T., Uotani, K., Yoshida, A., et al. (2017) Clinical Significance of Circulating miR-25-3p as A Novel Diagnostic and Prognostic Biomarker in Osteosarcoma. Oncotarget, 8, 33375.</mixed-citation></ref><ref id="hanspub.26792-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sita-Lumsden, A.R., Leach, D., Zivi, A., et al. (2017) A Circulating miRNA Signature to Help Prognos-ticate at Prostate Cancer Diagnosis. Journal of Clinical Oncology, 35, 108.</mixed-citation></ref><ref id="hanspub.26792-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Yokoi, A., Yoshioka, Y., Hirakawa, A., et al. (2017) A Combination of Circulating miRNAs for the Early Detection of Ovarian Cancer. Oncotarget, 8, 89-93.</mixed-citation></ref><ref id="hanspub.26792-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Santangelo, A., Imbruce, P., Gardenghi, B.A., et al. (2018) A MicroRNA Signature from Serum Exosomes of Patients with Glioma as Complementary Diagnostic Biomarker. Journal of Neuro-Oncology, 136, 51.</mixed-citation></ref><ref id="hanspub.26792-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Glinsky, Z.Z., Xi, L., et al. (2012) MicroRNA-132 Dysregulation in Schizophrenia Has Implications for Both Neurodevelopment and Adult Brain Function. Proceedings of the National Academy of Sciences of the United States of America, 109, 3125-3130.</mixed-citation></ref><ref id="hanspub.26792-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Liu, B., Qu, J., Xu, F., et al. (2015) MiR-195 Suppresses Non-Small Cell Lung Cancer By-Targeting CHEK1. Oncotarget, 6, 9445-9456. &lt;br&gt;https://doi.org/10.18632/oncotarget.3255</mixed-citation></ref><ref id="hanspub.26792-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Libman-Sokolowska, M., Drozdowicz, E. and Nasierowski, T. (2015) BDNF as a Biomarker in the Course and Treatment of Schizophrenia. Psychiatria Polska, 49, 1149-1158. &lt;br&gt;https://doi.org/10.12740/PP/37705</mixed-citation></ref><ref id="hanspub.26792-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Sun, X.Y., Zhang, J., Niu, W., et al. (2015) A Preliminary Analysis of microRNAas Potential Clinical Biomarker for Schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 168, 170-178.  
&lt;br&gt;https://doi.org/10.1002/ajmg.b.32292</mixed-citation></ref><ref id="hanspub.26792-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Lennertz, L., Quednow, B.B., Benninghoff, J., et al. (2011) Impact of TCF4 on the Genetics of Schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 261, S161-S165. &lt;br&gt;https://doi.org/10.1007/s00406-011-0256-9</mixed-citation></ref><ref id="hanspub.26792-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yan, J.J., Chang, Y., Zhang, Y.N., et al. (2017) miR-195 Inhibits Cell Proliferation via Targeting AEG-1 in Hepatocellular Carcinoma. Oncology Letters, 13, 3118-3126. &lt;br&gt;https://doi.org/10.3892/ol.2017.5826</mixed-citation></ref><ref id="hanspub.26792-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Sun, X.Y., Lu, J., Zhang, L., et al. (2015) Aberrant microRNA Expres-sion in Peripheral Plasma and Mononuclear Cells as Specific Blood-Based Biomarkers in Schizophrenia Patients. Journal of Clinical Neuroscience, 22, 570-574.  
&lt;br&gt;https://doi.org/10.1016/j.jocn.2014.08.018</mixed-citation></ref><ref id="hanspub.26792-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Chai, C., Song, L.J., Yang, B., et al. (2016) Circulating miR-199a-3p in Plasma and Its Potential Diagnostic and Prognostic Value in Glioma. European Review for Medical and Pharmacological Sciences, 20, 4885.</mixed-citation></ref><ref id="hanspub.26792-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chen, J., Yang, L., Wang, X., et al. (2017) Reduced Circulating mi-croRNA-203 Predicts Poor Prognosis for Glioblastoma. Cancer Biomark, 20, 521-526. &lt;br&gt;https://doi.org/10.3233/CBM-170335</mixed-citation></ref><ref id="hanspub.26792-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Q., Wang, C.J., Hou, Z.M., et al. (2017) Serum microRNA-376 Family as Diagnostic and Prognostic Markers in Human Gliomas. Cancer Biomark, 19, 137-144. &lt;br&gt;https://doi.org/10.3233/CBM-160146</mixed-citation></ref><ref id="hanspub.26792-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Tang, Y., Zhao, S., Wang, J., et al. (2017) Plasma miR-122 as a Po-tential Diagnostic and Prognostic Indicator in Human Glioma. Neurological Sciences, 38, 1087-1092. &lt;br&gt;https://doi.org/10.1007/s10072-017-2912-y</mixed-citation></ref><ref id="hanspub.26792-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Shi, W., Du, J., Qi, Y., et al. (2012) Aberrant Expression of Se-rum miRNAs in Schizophrenia. Journal of Psychiatric Research, 46, 198-204. &lt;br&gt;https://doi.org/10.1016/j.jpsychires.2011.09.010</mixed-citation></ref><ref id="hanspub.26792-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Liu, S., Yuan, Y.B., Guan, L.L., et al. (2013) miRNA-365 and miRNA-520c-3p Respond to Risperidone Treatment in First-Episode Schizophrenia after a 1 Year Remission. Chinese Medical Journal, 126, 2676-2680.</mixed-citation></ref></ref-list></back></article>